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Healthy heart • THEME
Hyperlipidaemia is a general term for elevated 
concentrations of any or all lipids in the plasma. 
Pr imary hyperl ip idaemia is rarely caused by 
genetic abnormalities and commonly caused by an 
unhealthy diet and inactivity. Primary hyperlipidaemia 
can be d iv ided into hypercholestero laemia, 
hypertriglyceridaemia and combined hyperlipidaemia. 
Secondary hyperlipidaemia can be due to diabetes, 
excess alcohol intake and adverse drug effects. 
 Coronary heart disease (CHD) is a major 
cause of morbidity and mortality in Australia.1 
The use of cholesterol lowering drugs, mainly 
statins, consumes over $880 million or 16% of 
the Pharmaceutical Benefit Scheme (PBS) budget, 
and this figure is growing.2 Statins are subsidised 
when used within PBS restrictions (Table 1). 
Alternate guidelines for lipid management, not 
based on cost benefit data, have been published in 
the Medical Journal of Australia.3 
Lipids and CHD – the evidence
There is a curvilinear relationship between total serum 
cholesterol and deaths from CHD.4 Consequently a drop 
in cholesterol level has a greater impact on reducing 
CHD death at the high end of the cholesterol range 
than at the lower end. However, while there is strong 
evidence that reducing cholesterol levels in individuals 
with existing CHD also reduces morbidity and mortality 
(Table 2), many individuals with high levels of cholesterol 
do not develop CHD, and 35% of those with CHD have 
cholesterol levels less than 5.2 mmol/L (Figure 1). 
 Increasing levels of HDL are associated with a reduced 
relative risk of CHD.3 Because of this relationship, the 
LDL/HDL ratio is useful in assessing the absolute risk of 
CHD in an individual and is used in risk factor calculators.5 
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Screening
The Royal Australian College of General Practitioners' 
Guidelines for preventive activities in general practice 
recommends screening (every 5 years) for cholesterol 
from the age of 45 years for the general population, and 
from 20 years for those with a first degree relative with 
premature CHD (men <55, women <65). For those with 
established CHD, or those at high risk, screening should 
be yearly.6 Mass screening is not recommended.7
Primary prevention
Serum cholesterol alone is a relatively poor predictor 
of individual CHD risk, so clinicians should be guided 
by absolute risk when making decisions about 
management and consider the relative benefits of 
treating other risk factors such as hypertension and 
smoking. Absolute risk should be calculated using risk 
factor tables that are usually based on the Framingham 
data, eg. the New Zealand Risk Calculator.5 
 Lifestyle improvements – smoking cessation, weight 
reduction, healthy eating (reduced intake of saturated 
fats and cholesterol) and regular physical exercise 
– remain the foundation for the primary prevention of 
CHD, especially as they have additional benefits for 
the health and welfare of an individual. A systematic 
review of individual lifestyle interventions, although 
showing modest improvements in cholesterol levels, 
did not demonstrate changes in all cause mortality. 
Similarly trials of multiple risk factor interventions, 
including drug therapy, for the primary prevention of 
CHD are not cost effective in those at low risk.8 
 Meta-analyses of primary prevention trials (mainly 
middle aged men without a history of myocardial 
infarction) using lipid lowering medication demonstrate 
a relative risk reduction of 30% (summary OR: 
0.70, 95%; CI: 0.62–0.79) for CHD events (nonfatal 
myocardial infarction and deaths from CHD) but not all 
cause mortality compared with placebo.9 
Secondary prevention
Meta-analysis of studies examining the effectiveness 
of statin therapy in adults with CHD indicate that use 
of statins at doses equivalent to 40 mg simvastatin 
lowers overall mortality by 16% (RR: 0.84, 95%; CI: 
0.79–0.89), cardiovascular mortality by 23% (RR: 0.77, 
95%; CI: 0.71–0.83), and CHD mortality or nonfatal 
MI by 25% (RR: 0.75, 5%; CI: 0.71–0.79).10 Benefits 
were seen within 2 years of starting therapy. The 
reduction in CHD risk in those taking statins increases 
with duration of treatment.11 A recent observational 
cohort study has indicated that groups (women and 
elderly men aged >65 years) that were not well 
represented in the original clinical trials derive similar 
but lesser benefits.12
Statin use in women and the elderly
Overseas research suggests that women do not get 
the same standard of care for CHD as men.13 However 
in Australia, there is some evidence that women 
– using age standardised rates – receive more statins 
at lower levels of risk than men.14 Although there is 
less trial data for women than men, it does appear 
Table 1. PBS criteria for statins
• The patient must have received dietary therapy (typically for 6 weeks)
• Fasting lipid levels must be checked after completion of dietary therapy
Patient characteristics Qualifying total cholesterol level
Patients with existing CHD Total cholesterol >4 mmol/L
Patients with:
• Diabetes mellitus Total cholesterol level >6.5 mmol/L
• Familial hypercholesterolaemia  or
•  Family history of CHD (first degree relative <60 years of age) Total cholesterol level >5.5 mmol/L with HDL <1 mmol/L 
• Hypertension 
Peripheral vascular disease
Patients with HDL <1 mmol/L  Total cholesterol level >6.5 mmol/L
Men aged 35–75 years Total cholesterol level >7.5 mmol/L
Postmenopausal women aged up to 75 years or a triglyceride level >4 mmol/L
Other patients not included above Total cholesterol level >9 mmol/L or a triglyceride level >8 mmol/L
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that women derive similar but smaller total mortality 
benefit for secondary prevention of ischemic heart 
disease. The benefits for primary prevention are less 
clear but it would appear reasonable that women be 
assessed for their absolute risk of developing CHD on 
the same basis as men and treated accordingly.
 A review of several studies that included patients 
over 65 years of age indicate that statins are effective 
in reducing cardiovascular events with the combined 
relative risk reduction being 21% (95% CI: 17–25) and 
numbers needed to treat 23 (95% CI: 17–29).15
Prevention and treatment of  stroke
Observational studies indicate that high levels of 
cholesterol are associated with increased risk of 
ischemic stroke, but low levels with increased risk of 
haemorrhagic stroke. Intervention studies show that 
statins reduce the risk of nonfatal stroke in patients 
with CHD or elevated serum cholesterol,16 however 
they do not have any benefit (or harm) in patients with 
a history of transient ischemic attack or stroke (and 
no history of CHD).17 Any possible increased risk of 
haemorrhagic stroke appears to be offset by reduction 
in CHD and ischemic stroke risk.18
Treatment of  peripheral vascular disease
Lipid lowering drugs may slow peripheral vascular 
disease progression,19 and trials of statins for the 
treatment of intermittent claudication show some 
benefits (eg. self reported waking distance).20,21
Pharmacological treatment of  
hyperlipidaemia
An outline of the pharmacological treatment of 
hyperlipidaemia is shown in Figure 2.
How low should you go?
In individuals with established heart disease or high 
absolute risk, the current targets recommended are: 
• LDL cholesterol <2.5 mmol/L
• total cholesterol <4.0 mmol/L
• HDL >1.0 mmol/L, and
• triglycerides <2.0 mmol/L.3 
Lower levels have been achieved in trials11,22 and the 
results of the recently reported TNT study confirm 
that lowering LDL cholesterol levels below current 
recommendations can have clinical benefit (an 
absolute risk reduction in major cardiovascular events 
of 2.2% but no reduction in overall mortality).23 Statin 
therapy appears to be subject to a law of diminishing 
returns as might be expected with the curvilinear 
relationship between cholesterol and CHD mortality. 
Given the evidence about compliance (see below) it 
may be prudent to spend time and money on those 
not accessing treatment – but at high risk – rather 
than incrementally reducing risk in those who are 
already benefiting.
Type of  statin
Comparison of the safety and effectiveness of statins 
is difficult because studies have enrolled subjects 
with different characteristics. Table 2 shows the major 
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Figure 1. Incidence of  CHD vs. total cholesterol 
Table 2. Type of statin, dosage and evaluation in clinical trials
Statin Dosage (max) Trials
Pravastatin  40 mg CARE38 
(Pravachol) (80 mg) WOSCOPS39 
  LIPID40
Simvastatin  20–40 mg  HPS11,16 
(Lipex, Zocor) (80 mg) 4S41
Lovastatin* 10–40 mg TexCAPS42 
(Mevacor)  (80 mg) 
Atorvastatin 10–20 mg  ASCOT43 
(Lipitor) (80 mg)
Rosuvastatin*  10–20 mg No clinical outcome trial  
(Crestor) (40 mg) evidence
*not available in Australia
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trials. Currently atrovastatin 20 mg (2.7 million scripts) 
and simvastin 20 mg (2.4 million scripts) are the 
most frequently prescribed statins in Australia and are 
effective at lowering total cholesterol.2 Rosuvastatin (5 
mg and 10 mg [not available in Australia]) appears to 
be the most effective at reducing LDL cholesterol from 
baseline for the same dose of drug in milligrams,24 
however concerns have been raised about its safety.25 
It should be remembered that another potent statin, 
cerivastatin, was withdrawn because of adverse 
effects. As there is no convincing evidence that any of 
the statins available in Australia is better than another, 
the choice should be based on cost. 
Problems with statin use
Side effects
Muscle aches and pains are among the most 
commonly reported side effects of patients taking 
statins in general practice. Myopathy (musculoskeletal 
symptoms and elevated creatine kinase) is the main 
side effect in patients taking statins and is more 
common with higher doses.26 Broadly, if the patient 
has symptoms and a creatine kinase four times the 
upper limit of normal, the statin should be ceased.27 
Statins can also be hepatotoxic and 3% of users can 
experience dose dependant elevations of alanine 
transaminase (ALT) and aspartate transaminase (AST). 
These rises often resolve without discontinuation 
of the statin. Nevertheless, patients with severe 
liver disease, chronic hepatitis or heavy alcohol 
consumption should not take statins. Rhabdomyolysis 
occurs in 0.04–0.2% of users, but deaths are rare 
(0.03 per 100 000 patient years).28 There is conflicting 
evidence about the effect of statins on memory 
(adverse effect) and cognitive function (improvement).
Discontinuation and compliance
Treating those at high risk is cost effective, but identifying 
patients at risk can be problematic. There is evidence that 
prescribing varies between,29 and within, countries.14,30 
Discontinuation rates range from 6–30% in clinical trials,15 
but are much higher in the community.31 Compliance 
in the elderly – at least – can also be poor with variable 
adherence to dosing schedules.32 No specific intervention 
*  Monitor side effects and stop treatment if: CK >5 times upper limit of normal 
range or severe muscle symptoms, or ALT is 2–3 times the upper limit of normal
Use a statin    
Check LFTs and 
creatine kinase
Monitor lipid levels  
Consider resin or 
ezetimibe if inadequate 
response
Monitor side effects*
Fibrate (or a fish oil)




Statin + fish oil
Check LFTs and 
creatine kinase
Monitor lipid levels
Statin + fibrate   





Hypertriglyceridaemia   
Combined hyperlipidaemia use either
OR
Figure 2. Pharmacological treatment of  hyperlipidaemia
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can be recommended to improve adherence to statin 
therapy at this time.33 
Use of  ezetimibe 
In patients intolerant of statins who do not achieve 
adequate reductions in serum cholesterol, ezetimibe 
(Ezetrol) is an alternative to resins, nicotinic acid or 
fibrates. Ezetimibe works by decreasing the absorption 
of cholesterol from the small intestine. By itself it can 
reduce cholesterol levels by 15–20% (10 mg dosage) and 
the addition of ezetimibe to statins can achieve additional 
reduction in cholesterol of 24%.34 It appears to be well 
tolerated, but we lack long term safety data. Likewise, 
there is no data (unlike statins) on the effect on CHD 
mortality, morbidity or all cause mortality. Adverse events 




Fibrates (gemfibrozil) are effective at lowering 
triglycerides and increasing HDL cholesterol. They have 
a role in combined hyperlipidaemia or predominant 
triglyceridaemia (Figure 2).
Bile acid binding resins
Bile acid binding resins (cholestyramine [Questran Lite] 
or colestipol [Colestid Granules]) have been shown to 
decrease LDL cholesterol levels by 15–25% and increase 
HDL cholesterol by 5%.35 There is a dose response 
effect, but adverse gastrointestinal effects limit the use 
of higher doses.
Fish oils
Fish oils – high in omega-3 polyunsaturated fatty acid 
– have a role in the management of hypertriglyceridaemia 
in combination with a statin. Whether a diet with 
moderate amounts (2 serves per week) of fish with 
high concentrations of omega-3 fatty acids is better than 
supplements is yet to be determined.
Future developments
C reactive protein 
Observational studies have reported an association 
between levels of C reactive protein (CRP) and morbidity 
and mortality from CHD.36 Statins reduce CRP levels 
as well as LDL cholesterol, so it has been speculated 
that there may be a role for monitoring both during 
treatment, and adjusting the type or dose of statin to 
obtain maximum benefit.37
Conclusion
There is strong evidence that treating middle aged men 
with statins who have established CHD will reduce overall 
mortality, CHD morbidity or mortality and stroke. There is 
weaker but reasonable evidence for treating men aged 
over 65 years and women of any age who have CHD, or 
people without CHD but at high risk. There may be some 
benefit for patients with stroke and peripheral vascular 
disease who are at risk of CHD. While discontinuation 
rates are high, the occurrence of serious adverse reactions 
is infrequent. Given the current epidemic of obesity and 
diabetes, further consideration needs to be given to the 
cost effectiveness of statins (vs. other strategies) for the 
prevention of CHD and reduction in mortality.
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